Table 1 Demographics and clinical characteristics of patients with severe COVID-19 at ICU admission.
Variables | Total patients (n = 43) | ECMO group (n = 22) | Non-ECMO group (n = 21) | P value | |
|---|---|---|---|---|---|
Demographics | Age, years | 61 ± 19 | 62 ± 18 | 60 ± 20 | 0.28 |
Sex, male/female | 35/8 | 18/4 | 17/4 | 1.00 | |
APACHE II score | 13 ± 19 | 14 ± 8 | 11 ± 9 | 0.02 | |
SOFA score | 6 ± 6 | 7 ± 6 | 4 ± 3 | < 0.01 | |
PaO2/FiO2 at ICU admission | 107 ± 94 | 89 ± 60 | 127 ± 109 | 0.01 | |
BMI, kg/m2 | 28.5 ± 16.4 | 30.0 ± 21.2 | 27.0 ± 8.4 | 0.50 | |
History | COPD, % | 14.0 | 18.2 | 9.5 | 0.66 |
Chronic renal disease, % | 9.3 | 9.1 | 9.5 | 1.00 | |
DM, % | 44.2 | 45.5 | 42.9 | 1.00 | |
Cardiovascular disease, % | 20.9 | 18.2 | 23.8 | 0.72 | |
Post-organ transplantation or other immunodeficiency, % | 0 | 0 | 0 | - | |
Smoking history, % | 65.8 | 76.2 | 52.9 | 0.18 | |
Under treatment for malignancy, % | 2.3 | 0.0 | 4.8 | 0.49 | |
Intervention | Prone position, % | 93.0 | 86.4 | 100 | 0.23 |
Mechanical ventilation, % | 100 | 100 | 100 | - | |
CRRT, % | 30.2 | 50.0 | 9.5 | < 0.01 | |
Medication | Favipiravir, % | 16.3 | 22.7 | 9.5 | 0.41 |
Remdesivir, % | 83.7 | 77.3 | 90.5 | 0.41 | |
Dexamethasone, % | 90.7 | 81.8 | 100 | 0.11 | |
Heparin, % | 100 | 100 | 100 | - | |
